Immune Therapeutics, Inc. (OTCMKTS: IMUN) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immunotherapy treatments. The company’s primary focus lies in harnessing the body’s immune system to target and eliminate cancerous cells and to modulate autoimmune conditions. Leveraging a diverse pipeline of biologics, small molecules and cellular therapies, Immune Therapeutics aims to address high-unmet medical needs where conventional therapies have fallen short.
At the core of Immune Therapeutics’ product portfolio are its lead immuno-oncology candidates, which include next-generation monoclonal antibodies designed to enhance tumor recognition and destruction. The company’s research efforts also encompass immune checkpoint inhibitors, cytokine modulators and viral vector platforms for oncolytic therapy. In addition to its internally developed pipeline, Immune Therapeutics collaborates with academic institutions and contract research organizations to accelerate preclinical validation and to broaden its therapeutic reach.
Headquartered in the United States, Immune Therapeutics maintains research facilities and partnerships across North America and Europe. These strategic alliances enable the company to access specialized expertise in translational medicine, bioinformatics and GMP manufacturing. By integrating multidisciplinary teams, Immune Therapeutics streamlines the transition of promising candidates from laboratory discovery through early-stage clinical trials.
Founded in the early 2010s, Immune Therapeutics has been guided by experienced leadership with deep roots in oncology drug development. Its executive team combines expertise in immunology, regulatory affairs and commercial strategy to advance the company’s mission. Under the direction of CEO James Sullivan, PhD, and Chief Scientific Officer Maria Chen, MD, PhD, Immune Therapeutics continues to expand its pipeline, pursue strategic collaborations and position itself as an emerging player in the rapidly evolving field of immunotherapy.
AI Generated. May Contain Errors.
Free IMUN Stock Alerts